HLS — HLS Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for HLS Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-15.3	-13.1	-23.6	-27.5	-19.7
Depreciation
Deferred Taxes
Non-Cash Items	1.64	0.123	3.92	9.53	2.93
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-7.67	-1.98	2.08	2.55	-1.8
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Taxes Payable
Net Change in Other Assets & Liabilities
Cash from Operating Activities	9.34	16.4	16.9	15.8	8
Capital Expenditures	-32.6	-0.69	-0.148	-0.189	-0.015
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-12.1	-3.82	-10	0	11.8
Acquisition of Business
Other Investing Cash Flow
Cash from Investing Activities	-44.7	-4.51	-10.1	-0.189	11.7
Financing Cash Flow Items	-0.658	0	-0.639	-1.36	-1.19
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	9.56	-11.4	-6.86	-14.6	-23.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-26.5	0.567	-0.456	1.23	-4.5